PMID- 34313776
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR  - 20220117
IS  - 2042-7158 (Electronic)
IS  - 0022-3573 (Linking)
VI  - 73
IP  - 10
DP  - 2021 Sep 7
TI  - beta-Caryophyllene attenuates lipopolysaccharide-induced acute lung injury via 
      inhibition of the MAPK signalling pathway.
PG  - 1319-1329
LID - 10.1093/jpp/rgab074 [doi]
AB  - OBJECTIVES: Acute lung injury (ALI) is a pulmonary manifestation of an acute 
      systemic inflammatory response, which is associated with high morbidity and 
      mortality. Accordingly, from the perspective of treating ALI, it is important to 
      identify effective agents and elucidate the underlying modulatory mechanisms. 
      beta-Caryophyllene (BCP) is a naturally occurring bicyclic sesquiterpene that has 
      anti-cancer and anti-inflammatory activities. However, the effects of BCP on ALI 
      have yet to be ascertained. METHODS: ALI was induced intratracheally, injected 
      with 5 mg/kg LPS and treated with BCP. The bone marrow-derived macrophages 
      (BMDMs) were obtained and cultured then challenged with 100 ng/ml LPS for 4 h, 
      with or without BCP pre-treatment for 30 min. KEY FINDINGS: BCP significantly 
      ameliorates LPS-induced mouse ALI, which is related to an alleviation of 
      neutrophil infiltration and reduction in cytokine production. In vitro, BCP was 
      found to reduce the expression of interleukin-6, interleukin-1beta and tumour 
      necrosis factor-alpha, and suppresses the MAPK signalling pathway in BMDMs, which is 
      associated with the inhibition of TAK1 phosphorylation and an enhancement of 
      MKP-1 expression. CONCLUSIONS: Our data indicate that BCP protects against 
      inflammatory responses and is a potential therapeutic agent for the treatment of 
      LPS-induced acute lung injury.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the Royal 
      Pharmaceutical Society. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Zhang, Yong
AU  - Zhang Y
AD  - Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of 
      Bengbu Medical College, Anhui Province Key Laboratory of Translational Cancer 
      Research, Bengbu Medical College, Bengbu, China.
FAU - Zhang, Haibo
AU  - Zhang H
AD  - Engineering Research Center of Cell & Therapeutic Antibody, Ministry of 
      Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Pathophysiology, Bengbu Medical College, Bengbu, China.
FAU - Wang, Muqun
AU  - Wang M
AD  - Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of 
      Bengbu Medical College, Anhui Province Key Laboratory of Translational Cancer 
      Research, Bengbu Medical College, Bengbu, China.
FAU - Qian, Feng
AU  - Qian F
AD  - Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of 
      Bengbu Medical College, Anhui Province Key Laboratory of Translational Cancer 
      Research, Bengbu Medical College, Bengbu, China.
AD  - Engineering Research Center of Cell & Therapeutic Antibody, Ministry of 
      Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
LA  - eng
GR  - 81573438/National Natural Science Foundation of China/
GR  - 1804h08020287/Key Research and Development Program of Anhui Province/
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Plant Extracts)
RN  - 0 (Polycyclic Sesquiterpenes)
RN  - 0 (Sesquiterpenes)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - BHW853AU9H (caryophyllene)
RN  - EC 2.7.11.25 (MAP Kinase Kinase Kinases)
RN  - EC 2.7.11.25 (MAP kinase kinase kinase 7)
RN  - EC 3.1.3.48 (Dual Specificity Phosphatase 1)
RN  - EC 3.1.3.48 (Dusp1 protein, mouse)
SB  - IM
MH  - Acute Lung Injury/chemically induced/*metabolism/prevention & control
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/therapeutic use
MH  - Cells, Cultured
MH  - Cytokines/metabolism
MH  - Dual Specificity Phosphatase 1/metabolism
MH  - Inflammation/chemically induced/*metabolism/prevention & control
MH  - Interleukin-1beta/metabolism
MH  - Interleukin-6/metabolism
MH  - Lipopolysaccharides
MH  - Lung/*drug effects/metabolism
MH  - MAP Kinase Kinase Kinases/metabolism
MH  - MAP Kinase Signaling System/*drug effects
MH  - Macrophages/*drug effects/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Phosphorylation
MH  - Phytotherapy
MH  - Plant Extracts/*pharmacology/therapeutic use
MH  - Polycyclic Sesquiterpenes/*pharmacology/therapeutic use
MH  - Sesquiterpenes/pharmacology/therapeutic use
MH  - Signal Transduction
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - acute lung injury
OT  - inflammation
OT  - lipopolysaccharide
OT  - mitogen-activated protein kinase phosphatase 1
OT  - transforming growth factor beta-activated kinase 1
OT  - beta-caryophyllene
EDAT- 2021/07/28 06:00
MHDA- 2022/01/18 06:00
CRDT- 2021/07/27 12:27
PHST- 2020/10/14 00:00 [received]
PHST- 2021/05/05 00:00 [accepted]
PHST- 2021/07/28 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
PHST- 2021/07/27 12:27 [entrez]
AID - 6329091 [pii]
AID - 10.1093/jpp/rgab074 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2021 Sep 7;73(10):1319-1329. doi: 10.1093/jpp/rgab074.